ACADIA Pharmaceuticals Inc. Long Term Debt (Total)

Long Term Debt (Total) of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Debt (Total) growth rates and interactive chart. Long-term debt is debt that matures in more than one year. The sum of long-term bank loans, debentures or bonds outstanding. Refers to interest-bearing debt. An indebted company pays interest on its debt, which is recorded on the income statement and reduces net income to common shareholders. Long-term debt is used in ratios lke Debt/Equity or Debt/Assets to determine the financial health of a business.


Highlights and Quick Summary

  • Long Term Debt (Total) for the quarter ending March 30, 2021 was $60.6 Million (a 36.26% increase compared to previous quarter)
  • Year-over-year quarterly Long Term Debt (Total) increased by 968.64%
  • Annual Long Term Debt (Total) for 2020 was $44.5 Million (a 598.95% increase from previous year)
  • Annual Long Term Debt (Total) for 2019 was $6.36 Million (a 3951.59% increase from previous year)
  • Annual Long Term Debt (Total) for 2016 was $157 Thousand (a 1862.5% increase from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Debt (Total) of ACADIA Pharmaceuticals Inc.

Most recent Long Term Debt (Total)of ACAD including historical data for past 10 years.

Interactive Chart of Long Term Debt (Total) of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $60.58
2020 $44.46 $45.34 $5.67 $6.09 $44.46
2019 $6.36 $6.38 $6.74 $6.75 $6.36
2016 $0.16 $0.2 $0.22 $0.16
2015 $0.24 $0.22
2014 $0.02
2013 $0.01 $0.0 $0.01
2010 $0.04 $0.05

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.